曾春贤博士一直从事肿瘤发病机制、细胞信号传导、基因表达调控等方面的研究，深入探讨了非编码RNA、微肽（micro-peptide）功能网络在调控肝纤维化、肿瘤增殖、凋亡、转移等过程中的作用以及血液循环miRNA在肝癌早期诊断中的应用，在国际期刊Lancet Oncology、Hepatology、Clinical Cancer Research、Oncogene、Cancer Letters、Nucleic Acids Research、RNA biology等杂志发表论文13篇（影响因子129），以第一或通讯作者发表论文6篇（影响因子45.5点），其中一篇为Faculty of 1000推荐阅读文章，H指数：11。

发明专利

1. 具有抑制肝癌转移功能的小肽及其制备方法与应用。曾春贤，黄宁。ZL 2020 1 1641680.7，2022-03-29

课题与基金

1. 国家自然科学基金青年科学基金，microRNA-122 调控肝癌上皮-间叶转换的机制及意义（81201631），23万元，2013.1-2015.12

2. 中国博士后科学基金，miR-122抑制肝癌EMT的机制研究（2012M510210），8万元（一等资助），2013.1-2014.12

3. 广东省自然科学基金，pri-miR-122与miR-122协同调控TGF-beta通路在肝癌发生发展中的作用及其机制研究（2018A0303130241），10万元，2018.5-2021.4

4. 广东省自然科学基金，miR-122在肝癌细胞上皮-间叶转换中的功能研究（S2012040007874），3万元，2012.10-2014.10

5. 深圳市科技研发资金基础研究（自由探索）项目，miR-122-TGF-β通路调控肝癌转移的作用及其机制研究（JCYJ20170307143928246），10万元，2017.5-2020.4

代表性学术成果

1. Zeng C, Sang Y, Wang FY, Zhuang SM*. Opposing roles of C/EBPalpha and eEF1A1 in Sp1-regulated miR-122 transcription. RNA biology, 2020,17:202-210. (IF:4.6，他引3次)

2. Song P, Zha M, Yang X, Xu Y, Wang H, Fang Z, Yang X, Xia W*, Zeng C*. Socioeconomic and geographic variations in the prevalence, awareness, treatment and control of dyslipidemia in middle-aged and older Chinese. Atherosclerosis, 2019,282:57-66. (IF: 5.1，他引11次)

3. Li X#, Li J#, Cai Y#, Peng S#, Wang J, Xiao Z, Wang Y, Tao Y, Li J, Leng Q, Wu D, Yang S, Ji Z, Han Y, Li L, Gao X, Zeng C*, Wen X*. Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett, 2018,418:211-220. (IF: 8.6，他引26次)

4. Zeng C#, Wang YL#, Xie C, Sang Y, Li TJ, Zhang M, Wang RZ, Zhang Q, Zheng L, Zhuang SM*. Identification of a novel TGF--miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget, 2015,6(14):12224-33. (他引43次)

5. Zhang JP#, Zeng C#, Xu L#, Gong J, Fang JH, Zhuang SM*. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/snail signaling. Oncogene, 2014,33(31):4069-76. (IF: 9.8，他引110次)

6. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM*. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology, 2010,52:1702-12. (IF: 17.4 Recommended Article by the Faculty of 1000 Biology，他引136次)

7. Zhao N#, Li S#, Wang R#, Xiao M, Meng Y, Zeng C, Fang JH, Yang J*, Zhuang SM*. Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells. Biochim Biophys Act, 2016,1859(7):933-42. (IF: 4.5，，他引26次)

8. Lin XJ#, Chong Y#, Guo ZW#, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM*. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol, 2015,16(7):804-15. (IF: 41.3，他引165次)

9. Zhu Y#, Lu Y#, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM*. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res, 2012,40:4615-25. (IF: 16.9，他引172次)

10. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY, Zhuang SM*. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology, 2011,54:1729-40. (IF: 17.4，他引237次)